QQQ   444.85 (+0.00%)
AAPL   171.95 (-0.78%)
MSFT   420.96 (-0.11%)
META   488.82 (-1.02%)
GOOGL   151.19 (+0.21%)
AMZN   180.50 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   905.28 (+0.31%)
NIO   4.51 (-3.43%)
AMD   180.38 (+0.44%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.24 (+1.38%)
MU   117.94 (-1.01%)
CGC   8.41 (-11.94%)
GE   175.39 (-2.63%)
DIS   122.28 (+1.07%)
AMC   3.65 (-15.90%)
PFE   27.84 (+0.22%)
PYPL   67.26 (+1.04%)
XOM   116.07 (+0.96%)
QQQ   444.85 (+0.00%)
AAPL   171.95 (-0.78%)
MSFT   420.96 (-0.11%)
META   488.82 (-1.02%)
GOOGL   151.19 (+0.21%)
AMZN   180.50 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   905.28 (+0.31%)
NIO   4.51 (-3.43%)
AMD   180.38 (+0.44%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.24 (+1.38%)
MU   117.94 (-1.01%)
CGC   8.41 (-11.94%)
GE   175.39 (-2.63%)
DIS   122.28 (+1.07%)
AMC   3.65 (-15.90%)
PFE   27.84 (+0.22%)
PYPL   67.26 (+1.04%)
XOM   116.07 (+0.96%)
QQQ   444.85 (+0.00%)
AAPL   171.95 (-0.78%)
MSFT   420.96 (-0.11%)
META   488.82 (-1.02%)
GOOGL   151.19 (+0.21%)
AMZN   180.50 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   905.28 (+0.31%)
NIO   4.51 (-3.43%)
AMD   180.38 (+0.44%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.24 (+1.38%)
MU   117.94 (-1.01%)
CGC   8.41 (-11.94%)
GE   175.39 (-2.63%)
DIS   122.28 (+1.07%)
AMC   3.65 (-15.90%)
PFE   27.84 (+0.22%)
PYPL   67.26 (+1.04%)
XOM   116.07 (+0.96%)
QQQ   444.85 (+0.00%)
AAPL   171.95 (-0.78%)
MSFT   420.96 (-0.11%)
META   488.82 (-1.02%)
GOOGL   151.19 (+0.21%)
AMZN   180.50 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   905.28 (+0.31%)
NIO   4.51 (-3.43%)
AMD   180.38 (+0.44%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.24 (+1.38%)
MU   117.94 (-1.01%)
CGC   8.41 (-11.94%)
GE   175.39 (-2.63%)
DIS   122.28 (+1.07%)
AMC   3.65 (-15.90%)
PFE   27.84 (+0.22%)
PYPL   67.26 (+1.04%)
XOM   116.07 (+0.96%)
NYSE:TARO

Taro Pharmaceutical Industries (TARO) Stock Price, News & Analysis

$42.20
-0.06 (-0.14%)
(As of 03:12 PM ET)
Today's Range
$42.15
$42.35
50-Day Range
$40.96
$43.33
52-Week Range
$22.89
$45.76
Volume
10,060 shs
Average Volume
52,630 shs
Market Capitalization
$1.59 billion
P/E Ratio
34.59
Dividend Yield
N/A
Price Target
$43.00

Taro Pharmaceutical Industries MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1.6% Upside
$43.00 Price Target
Short Interest
Healthy
0.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of Taro Pharmaceutical Industries in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.06 out of 5 stars

Medical Sector

803rd out of 939 stocks

Pharmaceutical Preparations Industry

371st out of 433 stocks

TARO stock logo

About Taro Pharmaceutical Industries Stock (NYSE:TARO)

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

TARO Stock Price History

TARO Stock News Headlines

Taro Pharmaceutical Industries Ltd. (TARO)
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Taro Pharmaceutical Industries Ltd
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)
Taro Provides Results for December 31, 2023
Sun Pharma To Acquire Taro Pharma For US$43.00/shr In Cash
Sun Pharmaceutical to Take Taro Private at $43/Shr
Taro Announces Merger Agreement with Sun Pharma
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
See More Headlines
Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/25/2024
Today
3/28/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
5/28/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
1,554
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$43.00
High Stock Price Target
$43.00
Low Stock Price Target
$43.00
Potential Upside/Downside
+1.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$25.44 million
Pretax Margin
12.17%

Debt

Sales & Book Value

Annual Sales
$572.95 million
Cash Flow
$1.75 per share
Book Value
$46.05 per share

Miscellaneous

Free Float
32,400,000
Market Cap
$1.59 billion
Optionable
Optionable
Beta
0.61
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Uday V. Baldota (Age 54)
    CEO & Director
  • Mr. William J. Coote (Age 69)
    VP, CFO & Chief Accounting Officer
  • Mr. Itamar Karsenti (Age 52)
    VP & Head of Operations
  • Mr. Avi Avramoff (Age 59)
    VP and Head of R&D
  • Mr. Itzik Baruch (Age 61)
    Vice President of Technical Services
  • Dr. Roman Kaplan (Age 77)
    Vice President of Scientific and Technical Compliance Manager
  • Mr. Erik Zwicker J.D. (Age 44)
    VP, General Counsel & Secretary
  • Mr. Ara Aprahamian (Age 56)
    Vice President of Sales & Marketing
    Comp: $616.14k
  • Ms. Michele Visosky (Age 58)
    VP & Head of Human Resource
  • Mr. Jayesh Shah (Age 68)
    Head of Procurement

TARO Stock Analysis - Frequently Asked Questions

Should I buy or sell Taro Pharmaceutical Industries stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TARO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TARO, but not buy additional shares or sell existing shares.
View TARO analyst ratings
or view top-rated stocks.

What is Taro Pharmaceutical Industries' stock price target for 2024?

1 equities research analysts have issued twelve-month price targets for Taro Pharmaceutical Industries' stock. Their TARO share price targets range from $43.00 to $43.00. On average, they predict the company's share price to reach $43.00 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price.
View analysts price targets for TARO
or view top-rated stocks among Wall Street analysts.

How have TARO shares performed in 2024?

Taro Pharmaceutical Industries' stock was trading at $41.78 at the start of the year. Since then, TARO stock has increased by 1.3% and is now trading at $42.31.
View the best growth stocks for 2024 here
.

Are investors shorting Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries saw a drop in short interest in the month of February. As of February 15th, there was short interest totaling 62,000 shares, a drop of 22.4% from the January 31st total of 79,900 shares. Based on an average daily volume of 51,000 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.8% of the shares of the stock are short sold.
View Taro Pharmaceutical Industries' Short Interest
.

When is Taro Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024.
View our TARO earnings forecast
.

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its quarterly earnings data on Thursday, January, 25th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.26. The business had revenue of $157.15 million for the quarter, compared to analyst estimates of $154.90 million. Taro Pharmaceutical Industries had a net margin of 7.48% and a trailing twelve-month return on equity of 3.26%.

What ETF holds Taro Pharmaceutical Industries' stock?

ARK Israel Innovative Technology ETF holds 58,404 shares of TARO stock, representing 2.19% of its portfolio.

What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO?

11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.00%), Brandes Investment Partners LP (0.00%), Murchinson Ltd. (0.00%), Northern Trust Corp (0.00%), ARK Investment Management LLC (0.15%) and Vanguard Group Inc. (0.00%).

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:TARO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners